XTRA:AFXMedical Equipment
Carl Zeiss Meditec (XTRA:AFX) Valuation After Strong FY 2024/25 Revenue Outlook and Margin Improvement Guidance
Carl Zeiss Meditec (XTRA:AFX) has investors’ attention after reporting solid revenue growth for fiscal 2024/25, helped by its Ophthalmology segment and the consolidation of DORC, alongside a constructive outlook for margins.
See our latest analysis for Carl Zeiss Meditec.
Despite the upbeat revenue and margin outlook, the stock’s 1 year total shareholder return of minus 16.9 percent and 3 year total shareholder return of roughly minus 64.4 percent show that sentiment has been weak. However,...